Patents by Inventor Rebecca Haberman
Rebecca Haberman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230277501Abstract: This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.Type: ApplicationFiled: February 8, 2023Publication date: September 7, 2023Inventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh, Arnold Bakker
-
Publication number: 20230033195Abstract: This invention relates to methods and compositions for treating central nervous system (CNS) disorders with cognitive impairment. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating central nervous system (CNS) disorders with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrphic lateral sclerosis and cancer-therapy-related cognitive impairment.Type: ApplicationFiled: March 14, 2022Publication date: February 2, 2023Inventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Publication number: 20220265685Abstract: The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment.Type: ApplicationFiled: January 25, 2022Publication date: August 25, 2022Inventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Publication number: 20220218665Abstract: This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).Type: ApplicationFiled: August 17, 2021Publication date: July 14, 2022Inventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Publication number: 20210244709Abstract: This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.Type: ApplicationFiled: September 14, 2020Publication date: August 12, 2021Inventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh, Arnold Bakker
-
Patent number: 10806717Abstract: This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.Type: GrantFiled: March 14, 2014Date of Patent: October 20, 2020Assignee: The Johns Hopkins UniversityInventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh, Arnold Bakker
-
Publication number: 20180015109Abstract: The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment.Type: ApplicationFiled: March 8, 2017Publication date: January 18, 2018Inventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Publication number: 20180010183Abstract: This invention provides methods for identifying genes associated with cognitive impairment and for identifying compounds useful in the treatment of cognitive impairment. The methods can in particular be used to identify genes associated with, and compounds useful in treating, cognitive impairment in aging.Type: ApplicationFiled: February 10, 2017Publication date: January 11, 2018Inventors: Michela Gallagher, Rebecca Haberman
-
Publication number: 20160038463Abstract: This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.Type: ApplicationFiled: March 14, 2014Publication date: February 11, 2016Inventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh, Arnold Bakker
-
Publication number: 20160030391Abstract: This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A) in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh, Arnold Bakker
-
Publication number: 20150094352Abstract: This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).Type: ApplicationFiled: April 25, 2014Publication date: April 2, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Publication number: 20140057903Abstract: This invention provides methods for identifying genes associated with cognitive impairment and for identifying compounds useful in the treatment of cognitive impairment. The methods can in particular be used to identify genes associated with, and compounds useful in treating, cognitive impairment in aging.Type: ApplicationFiled: July 10, 2013Publication date: February 27, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Michela Gallagher, Rebecca Haberman
-
Patent number: 8604075Abstract: This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).Type: GrantFiled: November 2, 2011Date of Patent: December 10, 2013Assignee: The Johns Hopkins UniversityInventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Patent number: 8510055Abstract: This invention provides methods for identifying genes associated with cognitive impairment and for identifying compounds useful in the treatment of cognitive impairment. The methods can in particular be used to identify genes associated with, and compounds useful in treating, cognitive impairment in aging.Type: GrantFiled: August 3, 2006Date of Patent: August 13, 2013Assignee: The Johns Hopkins UniversityInventors: Michela Gallagher, Rebecca Haberman
-
Publication number: 20120214859Abstract: This invention relates to methods and compositions for treating central nervous system (CNS) disorders with cognitive impairment. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating central nervous system (CNS) disorders with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis and cancer-therapy-related cognitive impairment.Type: ApplicationFiled: February 9, 2012Publication date: August 23, 2012Inventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Publication number: 20120046336Abstract: This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).Type: ApplicationFiled: November 2, 2011Publication date: February 23, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Publication number: 20110212928Abstract: The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment.Type: ApplicationFiled: February 9, 2011Publication date: September 1, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Publication number: 20100099735Abstract: This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).Type: ApplicationFiled: October 16, 2009Publication date: April 22, 2010Inventors: Michela Gallagher, Rebecca Haberman, Ming Teng Koh
-
Publication number: 20100081648Abstract: This invention provides methods for identifying genes associated with cognitive impairment and for identifying compounds useful in the treatment of cognitive impairment. The methods can in particular be used to identify genes associated with, and compounds useful in treating, cognitive impairment in aging.Type: ApplicationFiled: August 3, 2006Publication date: April 1, 2010Inventors: Michela Gallagher, Rebecca Haberman